Antifungal drug developer Scynexis's Q3 net loss widens

Reuters11-06

Antifungal drug developer Scynexis's Q3 net loss widens

Overview

Scynexis Q3 2025 net loss widens to $8.6 mln
Company receives $24.8 mln one-time payment from GSK, extending cash runway over two years

Outlook

Scynexis expects up to $146 mln in annual net sales milestones from BREXAFEMME relaunch
Scynexis's cash runway extends over two years, supporting SCY-247 development

Result Drivers

GSK PAYMENT - Scynexis received a one-time payment of $24.8 mln from GSK, resolving a disagreement over the Phase 3 MARIO study

Key Details

Metric	Beat/Miss	Actual	Consensus Estimate
Q3 Product Revenue		$334,000
Q3 Net Income		-$8.59 mln
Q3 Basic EPS		-$0.17
Q3 Operating Expenses		$8.74 mln
Q3 Pretax Profit		-$8.59 mln

Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the pharmaceuticals peer group is "buy"
Wall Street's median 12-month price target for SCYNEXIS Inc is $4.00, about 84.2% above its November 4 closing price of $0.63

Press Release: ID:nGNX84CtD5

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2581085921?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-06 06:53","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2581085921","market":"nz","top_or_hot":-1,"title":"Antifungal drug developer Scynexis's Q3 net loss widens","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>Antifungal drug developer Scynexis's Q3 net loss widens</title></head><body><p><span>Overview</span></p><ul><li><p>Scynexis Q3 2025 net loss widens to $8.6 mln</p></li><li><p>Company receives $24.8 mln one-time payment from GSK, extending cash runway over two years</p></li></ul><p><span>Outlook</span></p><ul><li><p>Scynexis expects up to $146 mln in annual net sales milestones from BREXAFEMME relaunch</p></li><li><p>Scynexis's cash runway extends over two years, supporting SCY-247 development</p></li></ul><p><span>Result Drivers</span></p><ul><li><p>GSK PAYMENT - Scynexis received a one-time payment of $24.8 mln from GSK, resolving a disagreement over the Phase 3 MARIO study</p></li></ul><p><span>Key Details</span></p><table><tbody><tr><td><p><span>Metric</span></p></td><td><p><span>Beat/Miss</span></p></td><td><p><span>Actual</span></p></td><td><p><span>Consensus Estimate</span></p></td></tr><tr><td><p>Q3 Product Revenue</p></td><td></td><td><p>$334,000</p></td><td></td></tr><tr><td><p>Q3 Net Income</p></td><td></td><td><p>-$8.59 mln</p></td><td></td></tr><tr><td><p>Q3 Basic EPS</p></td><td></td><td><p>-$0.17</p></td><td></td></tr><tr><td><p>Q3 Operating Expenses</p></td><td></td><td><p>$8.74 mln</p></td><td></td></tr><tr><td><p>Q3 Pretax Profit</p></td><td></td><td><p>-$8.59 mln</p></td><td></td></tr></tbody></table><p><span>Analyst Coverage</span></p><ul><li><p>The current average analyst rating on the shares is \"buy\" and the breakdown of recommendations is 3 \"strong buy\" or \"buy\", no \"hold\" and no \"sell\" or \"strong sell\"</p></li><li><p>The average consensus recommendation for the pharmaceuticals peer group is \"buy\"</p></li><li><p>Wall Street's median 12-month price target for <a href=\"https://laohu8.com/S/SCYX\">SCYNEXIS Inc</a> is $4.00, about 84.2% above its November 4 closing price of $0.63</p></li></ul><p>Press Release: <span>ID:nGNX84CtD5</span></p><p>For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.</p><p>(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Antifungal drug developer Scynexis's Q3 net loss widens</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAntifungal drug developer Scynexis's Q3 net loss widens\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-11-06 06:53</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>Antifungal drug developer Scynexis's Q3 net loss widens</title></head><body><p><span>Overview</span></p><ul><li><p>Scynexis Q3 2025 net loss widens to $8.6 mln</p></li><li><p>Company receives $24.8 mln one-time payment from GSK, extending cash runway over two years</p></li></ul><p><span>Outlook</span></p><ul><li><p>Scynexis expects up to $146 mln in annual net sales milestones from BREXAFEMME relaunch</p></li><li><p>Scynexis's cash runway extends over two years, supporting SCY-247 development</p></li></ul><p><span>Result Drivers</span></p><ul><li><p>GSK PAYMENT - Scynexis received a one-time payment of $24.8 mln from GSK, resolving a disagreement over the Phase 3 MARIO study</p></li></ul><p><span>Key Details</span></p><table><tbody><tr><td><p><span>Metric</span></p></td><td><p><span>Beat/Miss</span></p></td><td><p><span>Actual</span></p></td><td><p><span>Consensus Estimate</span></p></td></tr><tr><td><p>Q3 Product Revenue</p></td><td></td><td><p>$334,000</p></td><td></td></tr><tr><td><p>Q3 Net Income</p></td><td></td><td><p>-$8.59 mln</p></td><td></td></tr><tr><td><p>Q3 Basic EPS</p></td><td></td><td><p>-$0.17</p></td><td></td></tr><tr><td><p>Q3 Operating Expenses</p></td><td></td><td><p>$8.74 mln</p></td><td></td></tr><tr><td><p>Q3 Pretax Profit</p></td><td></td><td><p>-$8.59 mln</p></td><td></td></tr></tbody></table><p><span>Analyst Coverage</span></p><ul><li><p>The current average analyst rating on the shares is \"buy\" and the breakdown of recommendations is 3 \"strong buy\" or \"buy\", no \"hold\" and no \"sell\" or \"strong sell\"</p></li><li><p>The average consensus recommendation for the pharmaceuticals peer group is \"buy\"</p></li><li><p>Wall Street's median 12-month price target for <a href=\"https://laohu8.com/S/SCYX\">SCYNEXIS Inc</a> is $4.00, about 84.2% above its November 4 closing price of $0.63</p></li></ul><p>Press Release: <span>ID:nGNX84CtD5</span></p><p>For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.</p><p>(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4007","symbol_name":"制药","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251105:nL1N3WH1KS:1","article_id":"2581085921","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2581085921","pubTimestamp":1762383235,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Antifungal drug developer Scynexis's Q3 net loss widensOverviewScynexis Q3 2025 net loss widens to $8.6 mlnCompany receives $24.8 mln one-time payment from GSK, extending cash runway over two yearsOut","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4007":"制药","SCYX":"SCYNEXIS Inc"},"translate_title":"抗真菌药物开发商Scynexis第三季度净亏损扩大","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"SCYX":0.9},"content_text":"Antifungal drug developer Scynexis's Q3 net loss widensOverviewScynexis Q3 2025 net loss widens to $8.6 mlnCompany receives $24.8 mln one-time payment from GSK, extending cash runway over two yearsOutlookScynexis expects up to $146 mln in annual net sales milestones from BREXAFEMME relaunchScynexis's cash runway extends over two years, supporting SCY-247 developmentResult DriversGSK PAYMENT - Scynexis received a one-time payment of $24.8 mln from GSK, resolving a disagreement over the Phase 3 MARIO studyKey DetailsMetricBeat/MissActualConsensus EstimateQ3 Product Revenue$334,000Q3 Net Income-$8.59 mlnQ3 Basic EPS-$0.17Q3 Operating Expenses$8.74 mlnQ3 Pretax Profit-$8.59 mlnAnalyst CoverageThe current average analyst rating on the shares is \"buy\" and the breakdown of recommendations is 3 \"strong buy\" or \"buy\", no \"hold\" and no \"sell\" or \"strong sell\"The average consensus recommendation for the pharmaceuticals peer group is \"buy\"Wall Street's median 12-month price target for SCYNEXIS Inc is $4.00, about 84.2% above its November 4 closing price of $0.63Press Release: ID:nGNX84CtD5For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2581085921","isCrawlerRequest":true}